CD79b, a B-cell-specific antigen recently targeted for therapy in aggressive B-cell lymphomas, exhibits widespread expression on mature B-cell-derived lymphomas, as evidenced by immunohistochemical studies. The gene discussed is CD79B; the disease is B-cell non-Hodgkin lymphoma.